J P Morgan Chase & Co Reiterates Neutral Rating for Novartis AG (NVS)

Novartis AG (NYSE:NVS)‘s stock had its “neutral” rating reiterated by analysts at J P Morgan Chase & Co in a note issued to investors on Monday.

A number of other brokerages have also weighed in on NVS. Vetr lowered Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 price objective on the stock. in a report on Tuesday, April 25th. UBS AG reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday, May 30th. Zacks Investment Research lowered Novartis AG from a “hold” rating to a “sell” rating in a report on Monday, July 10th. Barclays PLC raised Novartis AG from an “underweight” rating to an “equal weight” rating in a report on Thursday, June 22nd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating on shares of Novartis AG in a report on Wednesday, March 22nd. Four analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. Novartis AG has a consensus rating of “Hold” and an average price target of $81.71.

Shares of Novartis AG (NVS) traded up 0.46% during trading on Monday, reaching $85.16. The company’s stock had a trading volume of 995,589 shares. The stock has a market cap of $201.45 billion, a price-to-earnings ratio of 32.02 and a beta of 0.73. Novartis AG has a one year low of $66.93 and a one year high of $86.90. The company has a 50-day moving average price of $82.65 and a 200-day moving average price of $77.25.

Novartis AG (NYSE:NVS) last issued its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. Novartis AG had a return on equity of 15.46% and a net margin of 13.10%. The firm had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. During the same period in the prior year, the business posted $1.23 EPS. The firm’s quarterly revenue was down 1.8% on a year-over-year basis. On average, equities research analysts forecast that Novartis AG will post $4.72 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “J P Morgan Chase & Co Reiterates Neutral Rating for Novartis AG (NVS)” was first published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://transcriptdaily.com/2017/07/19/j-p-morgan-chase-co-reiterates-neutral-rating-for-novartis-ag-nvs.html.

In other Novartis AG news, major shareholder Bioventures Ltd Novartis bought 266,667 shares of the company’s stock in a transaction on Wednesday, July 5th. The shares were bought at an average price of $15.00 per share, for a total transaction of $4,000,005.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.01% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Howe & Rusling Inc. increased its position in Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares during the last quarter. City Holding Co. boosted its stake in shares of Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock worth $102,000 after buying an additional 54 shares during the period. TCI Wealth Advisors Inc. boosted its stake in shares of Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock worth $103,000 after buying an additional 230 shares during the period. Archford Capital Strategies LLC boosted its stake in shares of Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock worth $110,000 after buying an additional 621 shares during the period. Finally, Kernodle & Katon Asset Management Group LLC boosted its stake in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock worth $111,000 after buying an additional 49 shares during the period. 11.29% of the stock is currently owned by institutional investors.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply